SAN DIEGO, Dec. 21, 2010 /PRNewswire/ — Arena Pharmaceuticals,
Inc. (Nasdaq:
ARNA) announced today that Jack Lief, Arena’s President and
Chief Executive Officer, will host a conference call and webcast
tomorrow, Wednesday, December 22, 2010, at 8:30 a.m. Eastern Time
(5:30 a.m. Pacific Time) to provide an update following the
completion of an end-of-review meeting with the US Food and Drug
Administration (FDA) for the lorcaserin New Drug Application
(NDA).
The conference call may be accessed by dialing 877.643.7155 for
domestic callers and 914.495.8552 for international callers. Please
specify to the operator that you would like to join the
“Lorcaserin” conference call. The conference call will be webcast
live under the investor relations section of Arena’s website at www.arenapharm.com, and will
be archived there for 30 days following the call. Please connect to
Arena’s website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About Arena PharmaceuticalsArena is a clinical-stage
biopharmaceutical company focused on discovering, developing and
commercializing oral drugs that target G protein-coupled receptors,
an important class of validated drug targets, in four major
therapeutic areas: cardiovascular, central nervous system,
inflammatory and metabolic diseases. Arena’s most advanced drug
candidate, lorcaserin, is intended for weight management. Arena’s
wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted
Eisai Inc. exclusive rights to market and distribute lorcaserin in
the United States following FDA approval of the New Drug
Application for lorcaserin.
Arena Pharmaceuticals(R) and Arena(R) are registered service
marks of the company.
Forward-Looking Statements Certain statements in this press
release are forward-looking
‘/>”/>
